Skip to main content
驱

驱动力 — Investor Relations & Filings

Ticker · 920275 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 479 across all filing types
Latest filing 2026-04-27 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920275

About 驱动力

Drive Power Bio-tech specializes in the research, development, and manufacturing of functional additives designed for animal nutrition. The company focuses on hematopoietic technology, providing solutions that enhance hemoglobin synthesis, strengthen immune responses, and support intestinal health. Its product portfolio includes specialized nutritional supplements that optimize metabolic processes and improve growth performance. By leveraging biotechnological innovation, the company develops high-efficiency additives aimed at enhancing physiological health and production efficiency in large-scale agricultural environments.

Recent filings

Filing Released Lang Actions
北京市中伦（广州）律师事务所关于广东驱动力生物科技集团股份有限公司2022年股权激励计划注销部分已获授但尚未行权的股票期权的法律意见书
Regulatory Filings Classification · 1% confidence The document is a law firm’s legal opinion (“法律意见书”) regarding the cancellation of unexercised stock options under the company’s 2022 equity incentive plan. It is not an earnings release, proxy statement, management discussion, or formal annual/interim report. Neither is it a director dealing notice, dividend announcement, share repurchase, or interest rate update. Instead, it is a compliance/legal disclosure document accompanying a share‐based compensation plan cancellation. This falls under the general “Regulatory Filings” category (RNS) as a statutory/legal submission rather than the plan itself or a standalone financial report.
2026-04-27 Chinese
拟续聘2026年度会计师事务所公告
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement regarding the proposed reappointment of an accounting/auditing firm for the 2026 financial audit, including board and audit committee resolutions. It does not present the audit report itself, nor full financial statements, nor details typical of an annual or interim report. It is not a narrative management discussion, not a capital or share issue notice, and not a dividend or governance code. Therefore, it falls under the fallback category “Regulatory Filings” (RNS).
2026-04-27 Chinese
华安证券股份有限公司关于广东驱动力生物科技集团股份有限公司使用闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 1% confidence The document is a detailed compliance disclosure and verification opinion by the sponsor (华安证券) regarding Guangdong Qidongli’s proposed use of idle proceeds for cash management, including background on fundraising, fund usage, risk controls, and board approval procedures. It does not constitute an annual or interim financial report, earnings release, proxy statement, or any other narrowly defined category. It is instead a regulatory filing under exchange rules on use of proceeds. As such, it best fits the fallback category “Regulatory Filings (RNS).”
2026-04-27 Chinese
董事、高级管理人员薪酬管理制度
Governance Information Classification · 1% confidence The document presents the full text of the company’s director and senior management remuneration management system – essentially an internal governance policy detailing how director and executive pay is structured, approved and reviewed. It is not announcing financial results, share transactions, legal proceedings or a shareholder vote outcome, nor is it a brief notice of publication. It is a detailed governance document laying out internal rules and procedures. This aligns with Governance Information (CGR).
2026-04-27 Chinese
关于注销2022年股权激励计划第三期及离退人员股票期权的公告
Regulatory Filings Classification · 1% confidence The document is a mandatory stock exchange announcement by Guangdong Drive Power Biotechnology Group Co., Ltd. detailing the cancellation of unvested/unauthorized stock options under its 2022 equity incentive plan. It describes board and committee approvals, legal opinions, and the quantitative impact on share options. It is not a report on financial results (10-K, IR, ER), nor an AGM or proxy solicitation, nor a director trading disclosure. It does not fall under Capital/Financing, M&A, or dividends. There is no specialized category for equity incentive cancellations, so it defaults to Regulatory Filings (RNS) as a general mandated disclosure.
2026-04-27 Chinese
2025年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 1% confidence The document is a standalone “专项报告” detailing the storage, management, and actual use of funds raised from a prior equity issuance. It is not an annual or interim financial report, nor a notice of publication. Rather, it is an update on the company’s fundraising–specifically the deployment and management of the proceeds. This matches the “Capital/Financing Update” category (CAP).
2026-04-27 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.